Prognosis
Novo in Supply Deal With Ypsomed for Auto-Injector Pens
- Danish maker of diet, diabetes drugs faces supply issues
- Ypsomed to expand manufacturing capacity for Novo injectors
Injection pen parts at the Novo Nordisk A/S production facilities in Hillerod, Denmark.
Photographer: Carsten Snejbjerg/BloombergThis article is for subscribers only.
Novo Nordisk A/S, which faces higher demand for its diabetes and weight-loss drugs than it can meet, signed a long-term agreement with Ypsomed Holding AG for the supply of auto-injectors.
Ypsomed is boosting its manufacturing capacity to make large quantities of auto-injectors that Novo can use for various drugs in clinical trials, the Swiss company said in a statement Wednesday. The stock rose as much as 5.2% to a record in early trading.